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Abstract
Recent advances in generating active proteins through refolding of bacterial inclusion body proteins
are summarized in conjunction with a short overview on inclusion body isolation and solubilization
procedures. In particular, the pros and cons of well-established robust refolding techniques such as
direct dilution as well as less common ones such as diafiltration or chromatographic processes
including size exclusion chromatography, matrix- or affinity-based techniques and hydrophobic
interaction chromatography are discussed. Moreover, the effect of physical variables (temperature
and pressure) as well as the presence of buffer additives on the refolding process is elucidated. In
particular, the impact of protein stabilizing or destabilizing low- and high-molecular weight additives
as well as micellar and liposomal systems on protein refolding is illustrated. Also, techniques
mimicking the principles encountered during in vivo folding such as processes based on natural and
artificial chaperones and propeptide-assisted protein refolding are presented. Moreover, the
special requirements for the generation of disulfide bonded proteins and the specific problems and
solutions, which arise during process integration are discussed. Finally, the different strategies are
examined regarding their applicability for large-scale production processes or high-throughput
screening procedures.
Background
Recombinant DNA technology made available several
simple techniques for transferring and efficiently express-
ing desired genes in a foreign cell. Thus, it was thought
that unlimited and inexpensive sources of otherwise rare
proteins would become accessible. It soon was observed
that the host cell had a great influence on the quality and
quantity of the produced recombinant protein. For exam-
ple, recombinant protein production in mammalian cells
yields a biologically active protein with all the required
posttranslational modifications. However, mammalian
cell cultivation is characterized by low volumetric yields
of the recombinant protein, long cultivation times and
requirements for expensive bioreactors and medium com-
ponents. All these points have a great impact on the pro-
duction costs. On the other hand, bacterial cultivation
processes are based on inexpensive media in which fast
growth and high cell concentrations can be obtained.
These high cell concentrations combined with higher pro-
duction rates of the bacterial expression system result in
higher volumetric productivities. However, the produc-
tion of recombinant proteins in bacteria such as
Escherichia coli frequently yields an inactive protein, aggre-
gated in the form of so-called inclusion bodies.
Published: 02 September 2004
Microbial Cell Factories 2004, 3:11 doi:10.1186/1475-2859-3-11
Received: 29 June 2004
Accepted: 02 September 2004
This article is available from: http://www.microbialcellfactories.com/content/3/1/11
© 2004 Vallejo and Rinas; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Microbial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
Page 2 of 12
(page number not for citation purposes)
Though, producing an inactive target protein in the form
of inclusion bodies is an important drawback, it also has
several advantages such as the high degree of purity of the
target protein in the aggregate fraction and the increased
protection from proteolytic degradation compared to the
soluble counterpart. Inclusion bodies have long been con-
sidered completely inert towards in vivo dissolution; only
recently it was shown that proteins can be resolubilized in
vivo from inclusion body deposits [1]. Although inclusion
bodies in general consist of inactive proteins, E. coli can be
the superior expression system compared to eukaryotic
expression systems when the activity of the recombinant
protein can be regained through refolding from the pro-
duced inclusion bodies. However, one needs to consider
that the decision to select a specific expression system fre-
quently is based on more trivial reasons such as staff
knowledge and available equipment and facilities of the
producing company/institute.
A good example to demonstrate the diverse routes that
can be used for recombinant protein production is the
manufacturing of tissue-type plasminogen activator (tPA).
This protein enables the dissolution of blood clots and is
used therapeutically for the treatment of myocardial inf-
arction, thrombosis, pulmonary embolism, and strokes.
To assure sufficient tPA for such a widespread application,
an economic production process is a necessity. From the
beginning, both the mammalian as well as the microbial
route were explored for the production of tPA [2]. tPA is a
fairly large (527 amino acids) monomeric protein con-
taining 17 disulfide bridges. Because of this complexity,
tPA was first produced in E. coli in the form of inclusion
bodies while the mammalian expression system yielded
an active protein that was secreted into the culture
medium. More recently, obtaining active tPA through
secretion into the periplasm of E. coli was attempted [3-5].
The early unsatisfactory yields have been improved [6,7]
rendering the E. coli secretion system as a future potential
alternative route to generate functional tPA. Other recom-
binant organisms such as yeast [8], fungi [9] or insect cells
[10] have not yet been considered as industrial producers
for this protein.
Initially, the recombinant tPA introduced into the market
was obtained from genetically engineered mammalian
cells [2]. At that time, generating biologically active tPA
from E. coli produced material was a process with a poor
overall yield [2]. Today, the majority of commercial tPA
(alteplase, Activase®) is still produced using a mammalian
expression system (Genentech: http://www.gene.com/
gene/products/information/cardiovascular/activase/). In
addition, an amino substituted tPA produced by the
mammalian expression system with increased half-life
(tenecteplase) was developed. Alternatively, a non-glyco-
sylated, truncated tPA (reteplase, Retavase®) produced in
E. coli in form of inclusion bodies and afterwards refolded
to its biologically active form is now on the market (Cen-
tocor: http://www.retavase.com/) and apparently gains
market share at the cost of the mammalian-derived prod-
uct(s) (see Genentech 2004 First Quarter Report).
Thus, continuous research effort focused on developing
new refolding techniques or improving existing ones by
including novel refolding aiding agents can make the bac-
terial inclusion body system an excellent alternative to the
mammalian expression system or other expression sys-
tems that can directly generate active proteins with a com-
plex disulfide bond structure. The foremost aim in
improving protein refolding from E. coli produced inclu-
sion bodies is to increase both the allowed protein con-
centrations during the refolding process and the final
refolding yield. Recent advances in this area are summa-
rized in conjunction with a short overview on inclusion
body isolation and solubilization procedures. Moreover,
the different techniques are discussed regarding their
applicability for large-scale production processes or high-
throughput screening procedures.
Isolation and solubilization of inclusion bodies
A high degree of purification of the recombinant protein
can be achieved by inclusion body isolation [for recent
reviews on various aspects of inclusion body formation
and renaturation of inclusion body proteins please refer
also to [11-18]]. Inclusion bodies are in general recovered
by low speed centrifugation of bacterial cells mechanically
disrupted either by using ultrasonication for small, French
press for medium, or high pressure homogenization for
large scale. Main protein contaminants in the crude inclu-
sion body fraction are proteins from the cell envelope, the
outer membrane proteins [19]. These proteins are not
integral inclusion body contaminants but coprecipitate
together with other insoluble cell material during inclu-
sion body recovery. Lysozyme-EDTA treatment before cell
homogenization facilitates cell disruption. Addition of
detergents such as Triton X-100 and/or low concentra-
tions of chaotropic compounds either prior to mechanical
cell breakage or for washing crude inclusion body prepa-
rations allow the removal of membrane proteins or other
nonspecifically adsorbed cell material [11-14].
After their isolation, inclusion bodies are commonly sol-
ubilized by high concentrations of chaotropic agents such
as guanidinium hydrochloride or urea. Although expen-
sive, guanidinium hydrochloride is in general preferred
due to its superior chaotropic properties. Moreover, urea
solutions may contain and spontaneously produce
cyanate [20], which can carbamylate the amino groups of
the protein [21]. In addition, inclusion body solubiliza-
tion by urea is pH dependent and optimum pH condi-
tions must be determined for each protein [22]. There areMicrobial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
Page 3 of 12
(page number not for citation purposes)
also reports that inclusion bodies can be solubilized at
extreme pH in the presence or absence of low concentra-
tions of denaturants [23-25]. However, extreme pH treat-
ments can result in irreversible protein modifications such
as deamidation and alkaline desulfuration of cysteine res-
idues [26]. Finally, inclusion bodies can be solubilized
with different types of detergents [27,28], low concentra-
tions of denaturants [29,30], or even by utilization of the
aggregation suppressor arginine [29]. Inclusion body pro-
teins solubilized under these mild conditions can possess
a native-like secondary structure [28-30], and may even
reveal some biological activity [29,31]. It has also been
demonstrated that the utilization of milder solubilization
conditions can lead to higher final refolding yields com-
pared to solubilization by high concentrations of gua-
nidinium hydrochloride or urea [27].
In addition to the solubilizing agent, the presence of low
molecular weight thiol reagents such as dithiothreitol
(DTT) or 2-mercaptoethanol is generally required. These
substances will reduce nonnative inter- and intramolecu-
lar disulfide bonds possibly formed by air oxidation dur-
ing cell disruption and will also keep the cysteines in their
reduced state [14,15]. Optimum conditions for disrup-
tion of existing disulfide bonds are found at mild alkaline
pH since the nucleophilic attack on the disulfide bond is
carried out by the thiolate anion. Residual concentrations
of reducing substances can negatively affect the refolding
process, thus, they are frequently removed (e.g. by dialy-
sis) before starting the refolding procedure. As an alterna-
tive, immobilized reducing agents (e.g. DTT;
VectraPrime™, Biovectra) could simplify reducing agent
removal by centrifugation after the solubilization process.
Finally, the pH must be reduced before the removal of the
reducing agent from the solution containing the solubi-
lized protein to prevent the formation of undesired
disulfide bonds.
Principles of refolding solubilized and unfolded proteins
Correct refolding versus aggregation
In general, the methods used for inclusion body solubili-
zation result in a soluble protein that is devoid of its
native conformation. This protein must then be trans-
ferred into conditions that allow the formation of the
native structure (e.g. low denaturant concentration).
Moreover, appropriate redox conditions have to be estab-
lished when the protein contains disulfide bonds in the
native state. When proper conditions for refolding are
identified, the refolding process can require a few seconds
or several days. During this period, the correct refolding
pathway competes, often in disadvantage, with misfold-
ing and aggregation of the target protein (Figure 1). Pro-
tein refolding involves intramolecular interactions and
follows first order kinetics [32-35]. Protein aggregation,
however, involves intermolecular interactions and, thus,
is a kinetic process of second or higher order, which is
favored at high protein concentrations [32-35]. In fact,
refolding yields commonly decrease with increasing ini-
tial concentrations of the unfolded protein independent
of the refolding method applied [35-40].
Aggregates are formed by nonnative intermolecular
hydrophobic interactions between protein folding inter-
mediates, which have not yet buried their hydrophobic
amino acid stretches (Figure 1). When the refolding proc-
ess is beyond these aggregation-prone intermediates, the
productive folding pathway is favored and aggregation
does not occur. Therefore, prevention of hydrophobic
intermolecular interaction during the first steps of refold-
ing is crucial to allow successful renaturation at high pro-
tein concentrations. Only recently a non-empirical
method for predicting the fate of proteins during the
refolding process was proposed [41]. It is based on the
second viral coefficient, which indicates the magnitude of
protein interaction under certain refolding conditions,
and thus its tendency to aggregate. However, though
being soluble in the refolding buffer is essential for a pro-
tein molecule to refold, it does not ensure that it will fold
into the native form.
Simplified model of correct folding versus misfolding and  aggregation Figure 1
Simplified model of correct folding versus misfolding and 
aggregation. The correct protein folding pathway (1) often 
competes with misfolding (2) and aggregation (3). Aggrega-
tion occurs among intermediates with exposed hydrophobic 
patches, which are buried in the correctly folded protein 
(blue lines, hydrophilic solvent-exposed parts of the protein; 
red lines: hydrophobic patches).Microbial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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Are further purification steps required after solubilization of inclusion 
bodies?
The recombinant target protein represents in general the
major fraction of the inclusion body proteins. Therefore,
refolding attempts can be undertaken directly after solubi-
lization of the inclusion bodies. Some reports, however,
claim higher refolding yields when the solubilized inclu-
sion body proteins are purified prior to the refolding
attempt [36,39,42,43]. Additional purification has been
recommended when the protein of interest represents less
than 2–5% of the total cell protein [26] or less than 2/3 of
the total inclusion body protein [42]. The type of contam-
inants can also be crucial for the success of the refolding
process. For example, typical non-proteinaceous contam-
inants of inclusion body preparations did not affect
refolding yields of lysozyme, while proteinaceous con-
taminants, which have a high tendency towards aggrega-
tion significantly reduced refolding yields [42]. Further
purification prior to the refolding attempt does not seem
to be required, even at low target protein concentrations,
when the solubilized inclusion body proteins are sub-
jected to refolding conditions during size exclusion chro-
matography where refolding and purification can occur
simultaneously [44]. All pros and cons of any further puri-
fication step have to be carefully evaluated as they cause
potential protein loss and additional production costs.
Techniques for protein refolding
Direct dilution
The simplest refolding procedure is to dilute the concen-
trated protein-denaturant solution into a refolding buffer
that allows the formation of the native structure of the
protein. Most frequently, the final protein concentration
after dilution is in the 1–10 µg/ml range in order to favor
the productive refolding instead of the unproductive
aggregation pathway. Though ideal at laboratory scale,
this technique has serious drawbacks during scale-up as
huge refolding vessels and additional cost-intensive con-
centration steps are required after renaturation.
A major improvement of this technique was the develop-
ment of a method where the solubilized, denatured pro-
tein is added in pulses or continuously into the refolding
buffer [37,40,45-47]. This technique still keeps the sim-
plicity of the direct dilution method while considerably
increasing the final concentration of the refolded protein.
Prerequisite is an appropriate knowledge of the folding
kinetics of the target protein. The addition of the concen-
trated protein-denaturant solution should occur at rates
slower than the rate-determining folding step of the target
protein, thereby avoiding the accumulation of aggrega-
tion-prone folding intermediates [37,46]. For pulse addi-
tion it has been recommended that 80% of the maximum
refolding yield should be reached before adding the next
pulse [14]. Other factors to be considered are the increas-
ing residual concentration of the denaturant with each
pulse, which should not surpass concentrations that affect
the refolding of the protein, and the amount of protein
added per pulse, which should be optimized in batch
experiments to minimize aggregation [14].
Membrane controlled denaturant removal
Another technique to transfer the solubilized and
unfolded protein to conditions allowing the formation of
the native structure is the utilization of dialysis and diafil-
tration systems for denaturant removal [e.g. [48-51]]. In
contrast to the direct dilution method, the change from
denaturing to native buffer conditions occurs gradually.
Thus, the protein passes through different regimes of
denaturant concentrations, where folding intermediates
that are prone to aggregation may become populated.
Most often, these techniques cause more aggregation dur-
ing refolding compared to the direct dilution method [e.g.
[52]]. Additionally, refolding yields can be negatively
affected by non-specific adsorption of protein to the
membrane. However, for some proteins and with the
appropriate denaturant removal rates, adapted to the
requirements of the target protein, high refolding yields at
high protein concentrations can be obtained [50-53]. A
fairly simple device was recently introduced allowing con-
tinuous or pulse refolding in a similar way as in the direct
dilution method [54].
Chromatographic methods for protein refolding
Protein refolding based on size exclusion chromatography
Buffer exchange for denaturant removal can also be car-
ried out by using size exclusion chromatography (SEC).
Most frequently, the denaturant-protein solution is
injected into a column previously equilibrated with the
refolding buffer [44,55-58]. Subsequent elution with the
refolding buffer results in a refolded protein in the eluate
fraction with a considerably higher concentration com-
pared to concentrations that can be reached by the simple
dilution technique [44,56,58]. Protein refolding may be
completed in the column or for proteins with slow folding
kinetics the final folding steps may occur in the eluate
fraction [44]. Aggregate formation is supposed to be
reduced either by physical separation of aggregation-
prone folding intermediates in the porous structures of
the gel [56] or, more likely, by resolubilization of formed
aggregates through the delayed running front of the
denaturant, which gives the solubilized aggregates
another opportunity to refold [14]. For proteins, which
exhibit superior refolding yields during gradual denatu-
rant removal, such as lysozyme, elution during SEC is
preferably performed by using a decreasing denaturant
gradient [38,52,59]. In specific cases, the denaturant
removal can be accompanied with other changes in the
buffer composition (i.e. pH) for further optimization of
refolding conditions [52]. An additional advantage of thisMicrobial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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chromatographic method is the concomitant purification
of the target protein during the refolding process [44].
Furthermore, some recent applications have shown the
feasibility of using SEC for continuous processes of pro-
tein refolding [60,61]. Also, SEC in combination with the
use of an annular chromatography system can be coupled
to an ultrafiltration and recycling unit for reinjection of
resolubilized aggregates, which may form during the
refolding process [60].
Some parameters for refolding using SEC are of key
importance. For example, protein aggregation during
sample injection can cause low refolding yields [62];
injecting the sample followed by an additional small vol-
ume of denaturant solution solves this problem
[44,52,62]. Also, optimum results can only be reached
when the properties of the chromatographic resin allow
efficient separation of the renatured target protein from
different folding intermediates, misfolded protein, and
aggregates that might form during the refolding process
[59,63,64]. In general, lower refolding yields are obtained
by injecting the denatured protein at high concentrations
[38,58,60,61,64] and/or by elution at high rates
[52,62,64]. Both conditions result in poor separation
among different folding intermediates thereby boosting
protein precipitation.
Matrix-assisted protein refolding
Attaching the solubilized and unfolded protein to a solid
support prior to changing from denaturing to native
buffer conditions is another approach to avoid the
unwanted intermolecular interaction between aggrega-
tion-prone folding intermediates. Binding of the solubi-
lized and unfolded protein to the matrix requires the
formation of a stable protein-matrix complex withstand-
ing the presence of chaotropic agents. However, after
changing to native buffer conditions, the detachment of
the refolded target protein from the matrix should easily
be accomplished. Several combinations of binding
motives and matrices have been employed for binding the
unfolded protein to the solid support. For example, pro-
teins with a natural occurring charged patch in the
unfolded chain, which binds to ion exchange resins
[59,65-67], or proteins containing artificially engineered
peptide tags such as the hexahistidine tag, which binds to
immobilized metal ions [59,68-70], or N- or C-terminal
hexaarginine tags binding to a polyanionic support [71],
or protein fusions with denaturant-resistant binding
domains, such as a glutathione S-transferase fragment,
which binds to an anion exchange matrix [72] or the cel-
lulose binding domain of the cellulose degrading mul-
tienzyme complex of the thermophilic bacterium
Clostridium thermocellum, which binds to a cellulose
matrix [73], have been employed. After binding, the
matrix-protein complex is brought to refolding conditions
by any of the above-mentioned techniques such as dilu-
tion [71], dialysis [68,73], or buffer exchange through
chromatography [59,66,69,70,72]. Finally, the refolded
protein can be detached from the matrix, e.g. in the case
hexahistidine-tagged proteins by elution with EDTA [69]
or imidazole [59,70] or by buffers with high ionic
strength in the case of proteins bound by ionic interac-
tions [59,65,66,71,72]. Due to the selective binding,
matrix-assisted refolding can combine the renaturation of
the target protein along with its purification from host cell
protein contaminants [69,70,72].
Refolding using hydrophobic interaction chromatography
Hydrophobic interaction chromatography (HIC) has also
been successfully used for protein refolding with concom-
itant removal of contaminating proteins during the rena-
turation process [74-78]. Unfolded proteins are applied to
the column at high salt concentrations and refolded and
eluted with a decreasing salt gradient. In contrast to the
above-mentioned chromatographic methods there is no
requirement for typical refolding aiding agents such as
arginine during the in-column refolding process. Moreo-
ver, refolding of the disulfide containing protein proinsu-
lin was even obtained in the absence of a redox system in
the mobile phase [76].
It has been proposed that refolding is facilitated during
HIC because unfolded proteins adsorb at high salt con-
centrations to the hydrophobic matrix and, thus, are not
prone to aggregation. Additionally, hydrophobic regions
of the protein that adsorb to the HIC matrix form micro-
domains around which native structure elements can
form. During migration through the column, the protein
will pass through several steps of adsorption and desorp-
tion, controlled by the salt concentration and hydropho-
bicity of the intermediate(s), resulting finally in the
formation of the native structure [75].
Physical and chemical features improving protein refolding 
yields
Apart from any of the above-mentioned techniques for
protein refolding, there are physical and chemical varia-
bles that have a great impact on the final yield of biologi-
cally active protein. For example, temperature as well as
the composition of the refolding buffer are important var-
iables influencing the final refolding yield.
Physical variables aiding protein refolding
The most important physical variable influencing the
refolding yield is the temperature [40,45,50,51]. Temper-
ature has a dual effect on the refolding process. On one
side, it influences the speed of folding and on the other it
influences the propensity towards aggregation of folding
intermediates with exposed hydrophobic patches. Also,
there is limited temperature range in which each proteinMicrobial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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is thermodynamically stable in a given buffer system [79].
In general, low temperatures support the productive fold-
ing pathway as hydrophobic aggregation is suppressed.
However, low temperatures also slow down the folding
rates, thus increasing the time required for renaturation
[51]. For refolding attempts of a new protein, 15°C has
been proposed as a good starting point [14].
Pressure was identified as another important physical var-
iable affecting protein structure as well as protein refold-
ing processes [80]. It was shown that high pressure up to
3 kbar can disrupt oligomeric protein structures [80] and
can dissolve protein aggregates and inclusion bodies
[81,82]. The disassembled protein monomers retain
native-like secondary structure up to 5 kbar [80]. After
gradual depressurization, they can reach their native state
even at high protein concentrations, because folding
intermediates prone to aggregate at atmospheric pressure
are prevented from aggregation by high pressure [81-83].
Chemicals aiding protein refolding
Certainly, L-arginine is nowadays the most commonly
used refolding aiding agent [14]. It impedes aggregate for-
mation by enhancing the solubility of folding intermedi-
ates, presumably by shielding hydrophobic regions of
partially folded chains. In addition, it has been shown
that numerous other low molecular weight additives such
as detergents, protein-stabilizing agents such as glycerol or
even low residual concentrations of denaturants improve
refolding yields by suppressing aggregation [14]. In addi-
tion, high-molecular weight additives such as polyethyl-
ene glycol were used successfully for enhancing protein
refolding yields [84]. More recently, low-molecular
weight non-detergent zwitterionic agents such as sulfo-
betaines, substituted pyridines and pyrroles and acid sub-
stituted aminocyclohexanes have been employed
successfully for protein renaturation [40,85-87]. Moreo-
ver, polymers with temperature-dependent hydrophobic-
ity were effectively applied for protein refolding at higher
temperatures [88,89]. The benefit of each of these refold-
ing aiding agents for a given renaturation system has to be
elucidated experimentally, as they are not equally advan-
tageous for all proteins. The mechanisms of interactions
of these refolding aiding agents with the folding interme-
diates remain often obscure although it is clear that all
these substances suppress aggregation in favor of the pro-
ductive folding pathway [90].
Micelles and liposomes as protein refolding aiding systems
Detergents [91,92] and phospholipids [93,94], in the
form of micelles and liposomes [95], respectively, as well
as mixed micelle systems formed by phospholipids and
detergents [92,95,96] have shown potential to aid protein
refolding. Most likely, illegitimate hydrophobic interac-
tions between folding intermediates are suppressed by
transient nonpolar interactions between the protein and
the micelle or liposome [91-93]. Additional transient
polar interactions in mixed micelles are supposed to be
responsible for higher refolding yields compared to only
detergent-based micelle systems [92,96]. Moreover, lipo-
somes linked covalently to chromatographic resins have
potential to combine renaturation and separation of the
refolded target protein [93,94].
Reversed micelles, formed when an aqueous detergent
solution is mixed with an organic solvent, can also facili-
tate protein refolding by avoiding aggregate formation
[97]. The denatured protein, once transferred to this solu-
tion, tries to avoid the organic phase, and, after reaching
the hydrophilic core of the reversed micelle, can refold as
a single molecule [97]. Recently, it was demonstrated that
protein precipitates can be solubilized by direct addition
into the reversed micellar system allowing refolding with
high yields at high protein concentrations [98-100]. Yet,
direct solubilization of inclusion bodies in reversed micel-
lar systems has not been reported. In addition, recovery of
refolded protein from these micellar structures is not eas-
ily accomplished [97,99].
Chemical and biological protein refolding aiding agents 
mimicking in vivo folding conditions
Natural chaperones
Chaperones are a group of proteins conserved in all king-
doms, which play a key role in assisting in vivo protein
folding and protecting cellular proteins from different
types of environmental stress by suppressing protein
aggregation. For example, the major E. coli chaperonin
GroEL is involved in the in vivo folding of 10% of all newly
synthesized proteins at normal growing conditions, and
of 30% under stress conditions [101]. GroEL assists pro-
tein folding by a first capturing step of aggregation-prone
folding intermediates [102]. The release of the folding-
competent form is then accomplished in an ATP-depend-
ent fashion through the action of the cochaperonin GroES
[102].
Natural chaperones have also been applied successfully to
refold various proteins in vitro [103]. However, their rou-
tine application is limited by their cost, the relatively high
chaperone concentration required (at least equimolar to
the target protein) and the need for their removal after the
refolding procedure [103,104]. Some procedures have
tried to overcome these limitations by utilizing immobi-
lized and reusable (mini)-chaperone systems [104-106].
Nevertheless, chaperone-based refolding processes are not
robust enough for large-scale processes [14].
Artificial chaperones
A further development of the detergent-based micellar
system mimics the two-step mechanism of chaperone-Microbial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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assisted protein folding. The capturing step is performed
by diluting the denatured protein into a detergent solu-
tion, which prevents protein aggregation through the for-
mation of mixed protein-detergent micelles [107-110].
Aqueous solutions of hydrogel nanoparticles (e.g. self-
assembly of hydrophobized polysaccharides such as cho-
lesterol-bearing pullulan) have been also used for the cap-
turing step [111]. The release of the folding-competent
protein is subsequently initiated by the addition of cyclo-
dextrins [107-112]. They are added in excess to the captur-
ing agent and strip the detergent from the protein-
detergent micelles through the formation of a tight deter-
gent-cyclodextrin complex. Long cyclodextrin polymers as
striping agent were reported to result in higher refolding
yields compared to monomeric cyclodextrins [113]. Also,
rapid addition of soluble cyclodextrins is thought to result
in higher refolding yields compared to slow addition
[108,109] or the utilization of immobilized cyclodextrins
[108,109]. However, at least for α-glucosidase similar
refolding yields were reported by stripping the detergent
either with soluble or immobilized cyclodextrins [114].
The utilization of these cyclodextrin polymer beads allows
simple removal of the cyclodextrin-detergent complex by
centrifugation and, moreover, these beads can be used in
expanded-bed columns in semicontinuous refolding
processes [114].
Liquid paraffin as pseudolipid bilayer membrane
In vivo, many proteins are transported through bilayered
membranes in an extended and partially unfolded form
either simultaneously or after their synthesis [115]. A
rather peculiar protein refolding procedure mimicking the
effect of a bilayered membrane was carried out in a three-
phase liquid system built up in a centrifugation tube
[116]. The upper phase contained an organic solution,
which was separated from the aqueous refolding buffer by
liquid paraffin. The protein, in an aggregated and dena-
tured form, was added to the organic phase and forced to
pass through the paraffin film into the refolding buffer by
centrifugation. This procedure was successfully applied
for the refolding of aggregated and denatured prepara-
tions of the model proteins RNase A and BSA.
Template-assisted protein folding
Several proteins are synthesized in their natural environ-
ment with amino-terminal propeptides usually located
between a signal sequence and the mature part of the pro-
tein. In vivo, these propeptides are known to play a key
role in assisting the correct folding of the mature part of
the protein [117]. In vitro studies have demonstrated that
they can facilitate the refolding in cis, when the denatured
mature protein is still linked to its propeptide prior to the
transfer into the refolding buffer, or in trans by including
the isolated propeptide into the refolding buffer [118-
120]. This propeptide assisted protein refolding can be
exploited for the renaturation of inclusion body proteins
either by synthesizing the mature part linked to its
propeptide, thus allowing later facilitated refolding
[121,122], or by synthesizing the mature protein and then
including the appropriate propeptide into the refolding
buffer [123].
Another method of template-assisted protein refolding
exploits the specific binding properties of monoclonal
antibodies to the target protein to reduce the time
required for protein refolding and to enhance the final
refolding yield [124,125]. This procedure does not work
with all antibodies and depends on the availability of spe-
cific antibody clones. Thus, it represents more a proof-of-
principle rather than a practical approach to generate
active proteins through refolding of inclusion body
proteins.
Proteins containing disulfide bonds: special requirements
In general, solubilization of inclusion body proteins by
chaotropic agents is carried out in the presence of reduc-
ing agents such as dithiothreitol or β-mercaptoethanol to
allow the disruption of nonnative disulfide bonds. Fol-
lowing solubilization, naturally disulfide-bonded pro-
teins have to be refolded under conditions, which permit
the formation of their native disulfide bonds. In the sim-
plest way, free cysteine residues can be oxidized by molec-
ular oxygen, a redox reaction catalyzed by Cu2+  ions
[126,127]. Though a cheap option, air oxidation is slow,
often results in mismatched disulfides, and is not suitable
for disulfide-bonded proteins, which also have free
cysteines [26].
Disulfide bonds are more efficiently formed when a mix-
ture of low molecular weight thiols (e.g. glutathione) in
their reduced and oxidized state is added to the refolding
buffer [126,128]. Best conditions for refolding of
disulfide-bonded proteins are commonly established
when the reduced form is present in excess and the pH is
slightly alkaline. These conditions allow rapid disulfide
exchange reactions until the protein reaches the most sta-
ble disulfide-bonded configuration, in general the native
state of the protein [26,126,128-130]. Recently, a novel
generation of aromatic thiols was developed which have
lower pKa values as the aliphatic thiols thus enabling
disulfide-bond formation at lower pH values [131,132].
These thiol reagents might be useful for the refolding of
proteins with limited stability at alkaline conditions. Also,
an immobilized disulfide-reshuffling system based on
thiol-carrying latex particles has recently been successfully
applied for the refolding of RNase A [133,134].
Naturally disulfide-bonded proteins in their reduced
states are often very unstable and exhibit a high tendency
towards aggregation, especially during the early stages ofMicrobial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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refolding [128]. These problems can be overcome by
modifying the reduced thiol groups in the unfolded pro-
tein, either by S-sulfonation [39,128,135,136] or by trans-
forming the free cysteines into mixed disulfides with the
oxidized form of a thiol reagent (e.g. glutathione)
[128,137]. These chemical modifications introduce
numerous charged residues into the protein, which pre-
vent the intermolecular interactions responsible for aggre-
gation. The chemically modified protein is then
transferred to refolding conditions. Correct disulfide
bond formation for S-sulfonated proteins is initiated by
supplementing the refolding buffer with the appropriate
redox system [39,128,135,136], or, for proteins with
mixed disulfides by adding trace amounts of the reduced
form of the thiol reagent [128,137].
Improvements of refolding yields of disulfide-bonded
proteins have also been achieved by using protein
disulfide isomerase (PDI) in combination with a redox
system. PDI is a folding catalyst that assists disulfide bond
formation in vivo [138] and was successfully implemented
for aiding disulfide bond formation during in vitro protein
refolding [139,140]. In some cases PDI did not show sig-
nificant effects on the refolding yield but significantly
increased the refolding rate [141]. However, residual con-
centrations of chaotropic agents in the refolding buffer,
especially guanidinium hydrochloride, can drastically
reduce PDI activity [142]. Traces of small peptides con-
taining the active site of PDI [143] and chemically synthe-
sized dithiol molecules mimicking PDI function [144-
146] have also shown potential to increase the in vitro
refolding yields generally obtained with the common
redox systems [143,146].
Process integration
Published refolding processes are often composed of
numerous and cumbersome steps, both downstream (e.g.
cell disruption, inclusion body isolation and purification
by several centrifugation and washing steps followed by a
final solubilization procedure) and upstream of the rena-
turation process (e.g. removal of aggregates and misfolded
protein and final purification of the correctly refolded tar-
get protein). Scale-up problems can arise when some of
these steps are not transferable to larger scale processes. As
an alternative to the common downstream process, inclu-
sion bodies can directly be solubilized from chemically
treated  E. coli cells [147-150] or in combination with
mechanical treatments [72]. Even more, inclusion body
solubilization directly from cells in the cultivation broth
is feasible as was shown for periplasmic [147] as well as
for cytoplasmic inclusion bodies [151]. A high degree of
purification, removal of cell debris and E. coli host cell
proteins, can be achieved by selective extraction of inclu-
sion body proteins combined with diafiltration [148],
aqueous two-phase extraction [147] or selective capture
by either expanded bed chromatography [72,149,151] or
by attachment to magnetic particles recoverable in high
gradient magnetic fields [152]. Major difficulties often
arise by the increase of broth viscosity due to release of
DNA after chemical treatment requiring its selective
removal e.g. by precipitation through spermidine addi-
tion [149,151] or preferably by treatment with DNA-
degrading enzymes [153]. Afterwards, the prepurified and
solubilized target protein can be subjected to refolding
conditions using any of the above-mentioned methods.
Moreover, there are reports on integrated processes where
solubilization of the target protein from chemically
treated cells is followed by a chromatographic process in
which the capturing step and removal of E. coli contami-
nants is followed directly and in the same operation unit
by refolding and subsequent purification [72,74]. Utiliza-
tion of refolding methods based on chromatographic
processes is additionally advantageous as they combine
refolding with an at least partial purification of the target
protein [44,69-72]. In addition, aggregates formed during
the refolding process can also be removed through chro-
matographic processes as they have a different retention
time compared to the correctly folded protein [56,64,67].
Finally, chromatographic processes can be performed
continuously [60,61] with the possibility to recycle aggre-
gates formed during the refolding process thus leading to
processes with refolding yields up to 100% [60].
Perspectives
After the first enthusiasm about protein production using
recombinant microorganisms, it was promptly under-
stood that obtaining an active form of the desired protein
was not a simple task. Many proteins form nonnative pre-
cipitates in form of inclusion bodies when synthesized in
bacteria and there is no universal refolding recipe for the
generation of native protein from solubilized inclusion
bodies. For any given protein, the best refolding condi-
tions still have to be determined empirically. Among a lot
of experience and "a good feeling for the best way", the
use of experimental design methodologies [154,155] and
further improvements in predicting the likelihood of
aggregation [41,156] may increase the speed for finding
the optimal refolding conditions for a given protein. Also,
less-established and new techniques as well as new refold-
ing aiding additives may become more widely used in the
near future. However, these techniques or new protein
refolding aiding substances await rigorous testing for
refolding of not only easy-going model proteins such as
RNase A but also for more recalcitrant inclusion body pro-
teins. Moreover, refolding strategies also have to be
adapted to the required quantity and final use of the
refolded protein. For therapeutic proteins needed in great
quantities more effort can be undertaken to identify the
best refolding conditions leading to high yields of the cor-
rectly folded protein. For a protein where just a fewMicrobial Cell Factories 2004, 3:11 http://www.microbialcellfactories.com/content/3/1/11
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milligrams are required for biochemical and/or structural
studies process optimization with respect to high yields is
not such a necessity. Also, special demands for high
throughput refolding screening arising from structural
genomic projects require robust strategies that will lead to
monodisperse refolded protein samples [157]. In this
case, the direct dilution method in combination with var-
iations in temperature and buffer composition is still the
best approach. Altogether, new strategies need to increase
the robustness of refolding processes and/or decrease the
costs to find acceptance for broader applications.
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